Show simple item record

dc.contributor.authorEvans, D Gareth R
dc.contributor.authorLalloo, Fiona
dc.contributor.authorCramer, A
dc.contributor.authorJones, E
dc.contributor.authorKnox, F
dc.contributor.authorAmir, E
dc.contributor.authorHowell, Anthony
dc.date.accessioned2011-02-05T12:06:39Z
dc.date.available2011-02-05T12:06:39Z
dc.date.issued2009-12
dc.identifier.citationAddition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. 2009, 46 (12):811-7 J Med Geneten
dc.identifier.issn1468-6244
dc.identifier.pmid19542080
dc.identifier.doi10.1136/jmg.2009.067850
dc.identifier.urihttp://hdl.handle.net/10541/121325
dc.description.abstractSelection for genetic testing of BRCA1/BRCA2 is an important area of healthcare. Although testing costs for mutational analysis are falling, costs in North America remain in excess of US$3000 (UK price can be 690 pounds). Guidelines in most countries use a 10-20% threshold of detecting a mutation in BRCA1/2 combined within a family before mutational analysis is considered. A number of computer-based models have been developed. However, use of these models can be time consuming and difficult. The Manchester scoring system was developed in 2003 to simplify the selection process without losing accuracy.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectBiological Tumour Markersen
dc.subject.meshBreast Neoplasms
dc.subject.meshDNA Mutational Analysis
dc.subject.meshFemale
dc.subject.meshGenes, BRCA1
dc.subject.meshGenes, BRCA2
dc.subject.meshHumans
dc.subject.meshROC Curve
dc.subject.meshTumor Markers, Biological
dc.titleAddition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing.en
dc.typeArticleen
dc.contributor.departmentUniversity of Manchester, Central Manchester Foundation Hospital NHS Trust, St Mary's Hospital, Manchester, UK. Gareth.evans@cmft.nhs.uken
dc.identifier.journalJournal of Medical Geneticsen
html.description.abstractSelection for genetic testing of BRCA1/BRCA2 is an important area of healthcare. Although testing costs for mutational analysis are falling, costs in North America remain in excess of US$3000 (UK price can be 690 pounds). Guidelines in most countries use a 10-20% threshold of detecting a mutation in BRCA1/2 combined within a family before mutational analysis is considered. A number of computer-based models have been developed. However, use of these models can be time consuming and difficult. The Manchester scoring system was developed in 2003 to simplify the selection process without losing accuracy.


This item appears in the following Collection(s)

Show simple item record